Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Corporate

09 May 2014 CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site’s manufacturing plant for plasma products, is the centerpiece of CSL’s $250 million expansion at its Broadmeadows site and will play an increasingly important role in the company’s global operations, particularly in the late-stage development of new types of hemophilia products. It is one of the largest and most advanced facilities of its kind in the world and will produce novel recombinant therapies on a large scale for international clinical trials.

> Read More
04 January 2013 CSL Behring and its Employees Give Back to their Communities by Supporting a Range of Charities Year-Round

CSL Behring and its employees helped numerous organizations throughout the United States in 2012, from local United Way chapters to patient advocacy groups, food banks and other agencies that provide vital services to people in need. With operations in King of Prussia, Pa., Kankakee, Ill. and Boca Raton, Fla., and CSL Plasma centers throughout the United States and sites in Knoxville, Tenn. and Indianapolis, Ind., the company and its employees impacted many people.

> Read More
03 December 2012 CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report

CSL Behring’s parent company, CSL Limited (ASX:CSL), reaffirms the company’s commitment to responsible business practice and sustainable development in its fourth Corporate Responsibility Report – Our Corporate Responsibility 2012. The report details CSL’s performance across key corporate responsibility priority areas for the period July 1, 2011 through June 30, 2012.

> Read More
09 September 2010 Patients With Hereditary Angioedema Often Misdiagnosed

CSL Behring announces the publication of its latest Key Issues Dialogue – Hereditary Angioedema (HAE) in the US. This ongoing series brings together thought leaders from the medical science and patient advocacy communities to examine critical issues affecting people with rare and serious diseases. The participants share and explore information and ideas that are important for patients, caregivers and healthcare providers. The current and previous Dialogues are available for download.

> Read More
29 December 2009 CSL Behring Awards Fourth Round of LEAD Grants

CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded four advocacy grants totaling $87,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support grassroots advocacy efforts by organizations committed to helping people who use plasma-derived or recombinant therapies manage their health conditions. Since the LEAD program’s inception in 2008, CSL Behring has awarded more than $340,000 in four semi-annual grant cycles. The deadline for the fifth round of grant requests is April 30, 2010.

> Read More
Page 3 of 6 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+